Form 4: Pulse Biosciences Director Granted New Stock Options

Maria Sainz, a Director at Pulse Biosciences, received grants for 53,104 common stock options with varying vesting schedules.

Summary

• Maria Sainz, a Director of Pulse Biosciences, Inc. (PLSE), was granted two tranches of stock options.
• The first grant, dated January 8, 2026, is for 50,000 shares of common stock with an exercise price of $14.72 per share.
• Vesting for the 50,000 options will occur with one-third of the shares vesting on the one-year anniversary of the grant, and the remaining shares vesting monthly over the subsequent two years, contingent on continued service.
• The second grant, dated February 5, 2026, is for 3,104 shares of common stock with an exercise price of $13.69 per share.
• The 3,104 options will vest in equal installments on March 5, 2026, and June 5, 2026, also subject to continued service.
• Both option grants have an expiration date ten years from their respective grant dates.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine compensation disclosure, indicating continued director engagement and alignment with shareholder interests through equity incentives. It is a neutral to slightly positive event.

Positives

• The grants align the director's interests with long-term shareholder value by providing equity-based compensation.
• Continued equity compensation for a director indicates ongoing commitment and engagement with the company's strategic direction.

Future Outlook

The filing details future vesting schedules for the granted stock options, extending through early 2029 for the larger grant, contingent on the reporting person's continued service.

Industry Context

StockSavvy.ai notes that granting stock options to directors is a common practice across industries, serving to align the interests of board members with those of shareholders by incentivizing long-term company performance and retention.

Comparison to Industry Standards

• Equity compensation for directors, such as stock options, is a standard practice in publicly traded companies, particularly in the biotechnology and medical device sectors where long-term development cycles are common.
• Without specific peer group compensation data, a direct comparison of the size and terms of these grants to industry benchmarks is not feasible based solely on this filing. However, the structure with multi-year vesting is typical for retention and performance alignment.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity grants are designed to align the director's financial interests with the long-term performance of the company, potentially benefiting shareholders through enhanced governance and strategic oversight.

Next Steps

• The granted stock options will vest according to their specified schedules, contingent on Maria Sainz's continued service as a director.
• The options will become exercisable on their respective vesting dates and expire ten years from their grant dates.

Key Dates

Keywords

Pulse Biosciences, PLSE, Maria Sainz, Stock Options, Insider Transaction, Form 4, Director Compensation, Equity Grant